PDCD1 and head and neck squamous cell carcinoma: In a study of HNSCC, exosomal CD73 derived from HNSCC cancer cells weakened the sensitivity of anti-PD-1 therapy by contributing to immunosuppression through activating the NF-κB pathway in TAMs [175].